Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk

Trial ID or NCT#

NCT01423201

Status

not recruiting iconNOT RECRUITING

Purpose

Transient ischemic attack (TIA) is a transient neurological deficit (speech disturbance, weakness…), caused by temporary occlusion of a brain vessel by a blood clot that leaves no lasting effect. TIA diagnosis can be challenging and an expert stroke evaluation combined with magnetic resonance imaging (MRI) could improve the diagnosis accuracy. The risk of a debilitating stroke can be as high as 5% during the first 72 hrs after TIA. TIA characteristics (duration, type of symptoms, age of the patient), the presence of a significant narrowing of the neck vessels responsible for the patient's symptoms (symptomatic stenosis), and an abnormal MRI are associated with an increased risk of stroke. An emergent evaluation and treatment of TIA patients by a stroke specialist could reduce the risk of stroke to 2%. Stanford has implemented an expedited triage pathway for TIA patients combining a clinical evaluation by a stroke neurologist, an acute MRI of the brain and the vessels and a sampling of biomarkers (Lp-PLA2). The investigators are investigating the yield of this unique approach to improve TIA diagnosis, prognosis and secondary stroke prevention. The objective of this prospective cohort study is to determine which factors will help the physician to confirm the diagnosis of TIA and to define the risk of stroke after a TIA.

Official Title

TIA Triage Trial and Evaluation of Vascular-Specific Inflammatory BiomarkerLp-PLA2 as a Stratification Tool for TIA Triage and Stroke Risk

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - Men and Women age greater than 18 year old - Symptoms suggestive of an acute TIA
Exclusion Criteria:
  1. - Patients with contraindication to brain imaging: MRI and CT. - Patient with persistent major deficit (NIHSS> or = 4) - Informed consent could not be obtained either directly from the patient or from legally authorized representative. - Severe coexisting or terminal systemic disease with like expectancy below 90 days or that may interfere with the conduct of the study.

Investigator(s)

Gregory W. Albers, MD
Gregory W. Albers, MD
Stroke and vascular neurologist
Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery
Paul George, MD, PhD
Paul George, MD, PhD
Stroke and vascular neurologist
Assistant Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery
Nirali Vora
Nirali Vora
Stroke and vascular neurologist, General neurologist, Neurohospitalist
Clinical Professor, Neurology & Neurological Sciences
Anna Finley Caulfield, MD
Anna Finley Caulfield, MD
Neurocritical care specialist
Clinical Professor, Neurology & Neurological Sciences
Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS
Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS
Stroke and vascular neurologist, Neurocritical care specialist
Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery
Neil Schwartz, MD, PhD
Neil Schwartz, MD, PhD
Stroke and vascular neurologist, General neurologist
Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery
Maarten Lansberg, MD, PhD
Maarten Lansberg, MD, PhD
Stroke and vascular neurologist, General neurologist
Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery

Contact us to find out if this trial is right for you.

Contact

Stephanie Kemp, BS
650-723-4481